Chemed (NYSE:CHE) Updates FY 2024 Earnings Guidance

Chemed (NYSE:CHE) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 23.300-23.700 for the period, compared to the consensus estimate of 23.520. The company issued revenue guidance of -. Chemed also updated its FY24 guidance to $23.30-23.70 EPS.

Chemed Trading Down 2.5 %

CHE stock traded down $14.19 during trading on Friday, reaching $559.15. The stock had a trading volume of 84,373 shares, compared to its average volume of 79,687. The stock’s 50 day moving average is $623.76 and its two-hundred day moving average is $590.54. The firm has a market cap of $8.45 billion, a PE ratio of 30.86, a PEG ratio of 2.48 and a beta of 0.42. Chemed has a 52 week low of $492.84 and a 52 week high of $654.62.

Chemed (NYSE:CHE) last posted its earnings results on Wednesday, April 24th. The company reported $4.68 earnings per share for the quarter, missing the consensus estimate of $5.09 by ($0.41). Chemed had a net margin of 12.36% and a return on equity of 31.69%. The company had revenue of $589.23 million for the quarter, compared to analysts’ expectations of $587.18 million. On average, research analysts anticipate that Chemed will post 21.99 EPS for the current year.

Chemed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Investors of record on Monday, February 26th were paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date of this dividend was Friday, February 23rd. Chemed’s dividend payout ratio (DPR) is 8.61%.

Wall Street Analyst Weigh In

CHE has been the topic of several research reports. Royal Bank of Canada increased their price target on shares of Chemed from $604.00 to $712.00 and gave the stock an outperform rating in a report on Monday, March 4th. Oppenheimer increased their price objective on Chemed from $625.00 to $650.00 and gave the company an outperform rating in a research note on Thursday, February 29th.

Insider Buying and Selling at Chemed

In related news, VP Brian C. Judkins sold 11,158 shares of the stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $645.00, for a total value of $7,196,910.00. Following the completion of the transaction, the vice president now directly owns 1,422 shares in the company, valued at $917,190. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Chemed news, VP Brian C. Judkins sold 11,158 shares of the company’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $645.00, for a total transaction of $7,196,910.00. Following the transaction, the vice president now directly owns 1,422 shares in the company, valued at $917,190. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael D. Witzeman sold 2,650 shares of the stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $643.14, for a total value of $1,704,321.00. Following the completion of the sale, the chief financial officer now owns 2,882 shares in the company, valued at $1,853,529.48. The disclosure for this sale can be found here. Insiders have sold 15,808 shares of company stock worth $10,184,531 in the last ninety days. 3.32% of the stock is owned by insiders.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.